Drug Trial Radar · NCT04243499
First-in-Human Study of ICT01 in Patients With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
293
Actual
Start
Mar 5, 2020
Primary completion
Oct 15, 2027
Study completion Oct 15, 2027
Sponsor
- Lead sponsor
- ImCheck Therapeutics, an Ipsen companyIndustry
- Sponsor type
- Industry
- First posted
- Jan 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 3 solid tumor indications for the combination of ICT01 plus pembrolizumab.
Conditions
- Solid Tumor, Adult
- Hematopoietic/Lymphoid Cancer
Interventions
IV ICT01Biological
humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with TEAES (Part 1)Time frame: From baseline to at least 6 months
- Percentage of participants with TEAES leading to discontinuation of study treatment or treatment modifications (Part 1)Time frame: From baseline to at least 6 months
- Percentage of participants with SAEs (Part 1)Time frame: From baseline to at least 6 months
- Percentage of participants with clinically significant change from baseline clinical laboratory abnormalities (Part 1)Time frame: From baseline to at least 6 months
- Percentage of participants with clinically significant change from baseline vital sign readings (Part 1)Time frame: From baseline to at least 6 months
- Percentage of participants with clinically significant change from baseline in 12-lead Electrocardiogram (ECG) readings (Part 1)Time frame: From baseline to at least 6 months
- Percentage of participants with clinically significant change from baseline physical examinations (Part 1)Time frame: From baseline to at least 6 months
- Duration of Complete Response (DCR) (Part 2)Time frame: From baseline to at least 6 months
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
City of Hope Comprehensive Cancer Center
Duarte, California
Yale Cancer Center
New Haven, Connecticut
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Montefiore Medical Center
The Bronx, New York
The University of Texas MD Anderson Cancer Center
Houston, Texas
US Oncology Research
Irving, Texas
University of Washington
Seattle, Washington
Institut Jules Bordet
Brussels, Belgium
Institut Bergonie
Bordeaux, France
Haut Leveque
Bordeaux, France
Centre Hospitalier Lyon Sud
Lyon, France
Centre Lyon Berard
Lyon, France
CHU Lyon
Lyon, France
Institut Paoli-Calmettes
Marseille, France
CHU Nantes
Nantes, France
Centre Antoine Lacassagne
Nice, France
Pitie-Salpetriere
Paris, France
Institut Curie
Paris, France
Gustave Roussy
Paris, France
CHU Poitiers
Poitiers, France
University Carl Gustav Carus Clinical Trial Unit
Dresden, Germany
universitatklinikum Wurburg
Würzburg, Germany
START Barcelone HM Nou Delfos
Barcelona, Spain
Vall d'Hebron Instiute of Oncology
Barcelona, Spain
START Madrid-FJD, Hospital Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Institute of Cancer Research
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.